Has Tad Gerlinger, MD received payments from drug or device companies?

Yes. Drug and device makers reported $641,507 in general payments to Tad Gerlinger, MD across 257 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Tad Gerlinger, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Tad Gerlinger, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Tad Gerlinger, MD

Adult Reconstructive Orthopaedic Surgery · Chicago, ILNPI 1922097971

Payments from drug & device makers

What this record shows

The money is spread across several categories — royalties or licence payments (42.2%), speaking fees and consulting fees — rather than concentrated in one kind of arrangement. Smith+Nephew accounts for 94.2% of it on its own, with 7 other manufacturers making up the rest. Among adult reconstructive orthopaedic surgery clinicians in IL with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$641,507in general payments, 2019–2025

Across 257 payments — averaging $2496.14 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Smith+Nephew$604K
Kyocera Medical Technologies, Inc.$27K
Graymont Professional Products IP, LLC$5K
Vertex$2K
KCI USA, Inc.$2K
Medical Device Business Services, Inc.$1K
plus $164 from 2 others

$227,099in research payments, 2019–2025

Across 45 payments — averaging $5046.64 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

Smith+Nephew$227K

What the payments were for

Royalty or licence$270,60742%
Consulting fees$82,20713%
Speaking & faculty fees$229,89036%
Travel & lodging$52,9258%
Food & beverage$5,7651%
Gifts$1140%

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Smith+Nephew	244	$604,420
Kyocera Medical Technologies, Inc.	5	$27,142
Graymont Professional Products IP, LLC	1	$5,000
Vertex	3	$2,011
KCI USA, Inc.	1	$1,600
Medical Device Business Services, Inc.	1	$1,170
Engage Uni, LLC	1	$114
Solventum Corporation	1	$50

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$641,507 in reported general payments places this provider in the 90th percentile of 67 adult reconstructive orthopaedic surgery providers in Illinois.

See all adult reconstructive orthopaedic surgery providers in Illinois →

Medicare billing

Part B allowed, 2024

$471,631

Medicare patients

780

Services billed

7,645

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
Gabapentin	74	$573
Oxycodone Hcl	95	$483
Amoxicillin	216	$483
Ondansetron OdtOndansetron	76	$448
Tramadol Hcl	178	$448
Meloxicam	110	$345
Cefadroxil	57	$339
Clindamycin Hcl	47	$72

Paid to pharmacies, not to this prescriber.

Other adult reconstructive orthopaedic surgery in Chicago

Denis NamChicago$3.2M
Craig della ValleChicago$2.4M
Hany BedairChicago$1.1M
Linda SuleimanChicago$898K
Henry FinnChicago$523K
Vasili KarasChicago$264K
Brett LevineChicago$250K
Sara WallaceChicago$148K
Joshua JacobsChicago$72K
William ThomasChicago$27K

See the full list for Illinois →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →